Article
Clinical Neurology
Jeffrey T. Guptill, Michael Benatar, Volkan Granit, Ali A. Habib, James F. Howard, Carolina Barnett-Tapia, Richard J. Nowak, Ikjae Lee, Katherine Ruzhansky, Mazen M. Dimachkie, Gary R. Cutter, Henry J. Kaminski
Summary: The lack of standardization in outcome measures in myasthenia gravis clinical trials has led to confusion and variability in data. A group of experts summarized key outcome measures and made recommendations for improvements. Changes to outcome measure instructions and specific instruments were proposed, with a focus on the Quantitative MG score requiring the most attention. Training materials and revised documents will be made available to study teams.
Article
Clinical Neurology
Ivo Bozovic, Jelena Ilic Zivojinovic, Stojan Peric, Marko Kostic, Vukan Ivanovic, Dragana Lavrnic, Ivana Basta
Summary: Although a significant number of MG patients were in remission after 10 years, their QoL was still reduced. Factors such as depression and poor disease acceptance may impact the level of QoL in patients.
JOURNAL OF NEUROLOGY
(2022)
Article
Immunology
Zhe Ruan, Yonglan Tang, Chunhong Li, Chao Sun, Ying Zhu, Zhuyi Li, Ting Chang
Summary: This study investigated the safety of COVID-19 vaccination in 22 patients with myasthenia gravis, finding that the majority did not experience symptom worsening within 4 weeks post-vaccination. Most patients received inactivated vaccines and showed no adverse effects, supporting the recommendation for vaccination in MG patients during the ongoing pandemic.
Article
Multidisciplinary Sciences
Koji Sekiguchi, Kei Ishizuchi, Tsubasa Takizawa, Haruhiko Motegi, Munenori Oyama, Jin Nakahara, Shigeaki Suzuki
Summary: This study investigated factors associated with anemia and its negative impact on the quality of life in female patients with myasthenia gravis. The results showed that patients with anemia had greater severity of myasthenia gravis, and a history of anemia was associated with immunosuppressive treatment. There was a correlation between hemoglobin levels and the quality of life score. Therefore, anemia may negatively affect the quality of life in female patients with myasthenia gravis.
Article
Multidisciplinary Sciences
Agnete Overgaard Donskov, Akiko Shimoda, Lotte Vinge, Peter Svensson, Henning Andersen
Summary: This pilot study found that patients with myasthenia gravis had more oral complaints and lower bite force compared to healthy controls, but did not show significantly different functional chewing patterns.
Article
Medicine, Research & Experimental
Rui Zhao, Ying Wang, Xiao Huan, Huahua Zhong, Zhirui Zhou, Jianying Xi, Yuwei Da, Lin Lei, Ting Chang, Zhe Ruan, Lijun Luo, Shengnan Li, Huan Yang, Yi Li, Sushan Luo, Chongbo Zhao
Summary: The study aimed to develop and validate a predictive nomogram for assessing short-term outcomes in patients with anti-acetylcholine receptor subtype gMG, showing good performance in predicting minimal symptom expression based on baseline clinical characteristics.
JOURNAL OF TRANSLATIONAL MEDICINE
(2021)
Article
Clinical Neurology
Elena Cortes-Vicente, Rodrigo Alvarez-Velasco, Francesc Pla-Junca, Ricard Rojas-Garcia, Carmen Paradas, Teresa Sevilla, Carlos Casasnovas, Maria Teresa Gomez-Caravaca, Julio Pardo, Alba Ramos-Fransi, Ana Lara Pelayo-Negro, Gerardo Gutierrez-Gutierrez, Janina Turon-Sans, Adolfo Lopez de Munain, Antonio Guerrero-Sola, Ivonne Jerico, Maria Asuncion Martin, Maria Dolores Mendoza, German Moris, Beatriz Velez-Gomez, Tania Garcia-Sobrino, Elba Pascual-Goni, David Reyes-Leiva, Isabel Illa, Eduard Gallardo
Summary: This study identified that 8.5% of MG patients were drug-refractory, with these patients being more commonly female, younger at onset, and more likely to have a generalized form of the disease, bulbar symptoms, and life-threatening events compared to non-drug-refractory patients. A significant percentage of drug-refractory patients experienced side effects to the drugs used, while a larger proportion of non-drug-refractory patients achieved remission or minimal manifestations at the end of follow-up. New more specific drugs are needed to effectively treat drug-refractory MG patients.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
(2022)
Article
Clinical Neurology
Sven Zupanic, Martina Peric Situm, Maja Majdak, Mirna Karakas, Silvio Basic, Davor Sporis
Summary: A study on hospitalized myasthenia gravis patients with COVID-19 found that most patients were successfully treated without the need for respiratory support, while some required mechanical ventilation. The key to treatment lies in the severity of the patients' condition and the choice of treatment methods.
ACTA NEUROLOGICA BELGICA
(2021)
Article
Medicine, General & Internal
Hongxi Chen, Lingyao Kong, Ying Zhang, Xue Lin, Ziyan Shi, Qin Du, Xiaofei Wang, Yanlin Lang, Linjun Cai, Zichao Mou, Wenqin Luo, Shuangjie Li, Hongyu Zhou
Summary: This study revealed the importance of monitoring myocardial injury biomarkers in patients with myasthenia gravis (MG) and identified age, infection, myasthenic crisis, thymoma, and immune checkpoint inhibitor therapy as independent risk factors for elevated troponin T (TnT) levels. High TnT levels, female sex, thymoma, and infection were identified as independent risk factors for death.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Mariela L. Paz, Francisco J. Barrantes
Summary: Myasthenia gravis is a disease that affects the signaling at the cholinergic neuromuscular junction, mainly caused by autoimmune diseases. Research also shows that cholesterol's rich content at the postsynaptic membrane is related to the modulation of nicotinic receptors, with discussions on the pathophysiology of myasthenia gravis affected by cholesterol.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
(2021)
Article
Urology & Nephrology
Akira Takahashi, Takamasa Miyauchi, Narihito Tatsumoto, Mercury Y. Lin, Jean Hou, Toshiki Doi, Takao Masaki, Michifumi Yamashita
Summary: The study examined kidney biopsies from patients with thymoma and/or MG, identifying a wide spectrum of kidney diseases with low-grade immune complex deposition affecting the glomerular and tubulointerstitial compartments. These findings suggest a role of immunologic dysregulation in the pathogenesis of thymic disease-associated nephropathy.
CLINICAL KIDNEY JOURNAL
(2021)
Article
Clinical Neurology
Madeline Singer, Sami Khella, Shawn Bird, Paul McIntosh, Bandhu Paudyal, Anil Wadhwani, Colin Quinn, Chafic Karam
Summary: This study describes the use of efgartigimod in the treatment of gMG and finds it to be efficacious, well tolerated, and safe. Efgartigimod can be considered as an add-on therapy, a bridge therapy, or as a monotherapy for patients with difficulty tolerating other treatments.
Article
Clinical Neurology
Li Yang, Shougang Guo, Xiuying Chen
Summary: This study analyzed the clinical features of MG in combination with afterdischarges and compared the characteristics of afterdischarges in patients with different serum antibodies. It was found that the afterdischarges differed distinctly between patients with MuSK-Ab and AchR-Ab, with afterdischarges decreasing on subsequent stimulations in MuSK-MG patients but continuing to occur in AchR-MG patients. The characteristics of afterdischarges on RNS can help in distinguishing their synaptic or neurogenic nature.
FRONTIERS IN NEUROLOGY
(2021)
Review
Oncology
Mingbo Tang, Yifeng Shao, Junxue Dong, Xinliang Gao, Shixiong Wei, Jianzun Ma, Yang Hong, Zhiqin Li, Taiyu Bi, Yipeng Yin, Wenyu Zhang, Wei Liu
Summary: This study used a meta-analysis to examine the incidence of postoperative myasthenia gravis (PMG) and risk factors in patients with non-MG thymoma. The results showed that the incidence of PMG in preoperative patients with non-MG thymoma was 8%. Preoperative seropositive acetylcholine receptor antibody, open thymectomy, non-R0 resection, WHO type B, and postoperative inflammation were identified as risk factors for PMG.
FRONTIERS IN ONCOLOGY
(2023)
Article
Clinical Neurology
Yuta Kojima, Akiyuki Uzawa, Yukiko Ozawa, Manato Yasuda, Yosuke Onishi, Hiroyuki Akamine, Naoki Kawaguchi, Keiichi Himuro, Yu-ichi Noto, Toshiki Mizuno, Satoshi Kuwabara
Summary: The study revealed that a high RR-AChRAb is associated with a favorable outcome at 1-year post-treatment, indicating that re-measuring AChR Ab within 100 days of therapy initiation may be useful for predicting the treatment outcome of AChR Ab-positive MG patients.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2021)
